Vital Therapies’ (NASDAQ:VTL) “Buy” Rating Reaffirmed at Raymond James Financial

Raymond James Financial reissued their buy rating on shares of Vital Therapies (NASDAQ:VTL) in a research note released on Tuesday, December 5th.

A number of other brokerages also recently commented on VTL. BidaskClub raised shares of Vital Therapies from a buy rating to a strong-buy rating in a report on Thursday, October 5th. Zacks Investment Research downgraded shares of Vital Therapies from a hold rating to a sell rating in a research note on Thursday, October 5th. Finally, ValuEngine raised shares of Vital Therapies from a strong sell rating to a sell rating in a research note on Saturday, October 21st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $8.00.

Shares of Vital Therapies (NASDAQ VTL) opened at $5.55 on Tuesday. Vital Therapies has a 12-month low of $2.25 and a 12-month high of $6.50.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Wednesday, October 25th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. During the same period in the previous year, the business earned ($0.32) earnings per share. sell-side analysts predict that Vital Therapies will post -1.26 EPS for the current fiscal year.

In other news, Director Muneer A. Satter acquired 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were bought at an average cost of $4.77 per share, with a total value of $238,500.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Muneer A. Satter acquired 150,000 shares of the stock in a transaction on Monday, December 11th. The shares were acquired at an average cost of $4.89 per share, for a total transaction of $733,500.00. The disclosure for this purchase can be found here. Insiders have bought 300,000 shares of company stock valued at $1,520,000 over the last quarter. Insiders own 32.60% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. grew its holdings in Vital Therapies by 0.9% in the third quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock valued at $13,145,000 after purchasing an additional 23,810 shares during the period. Granahan Investment Management Inc. MA grew its holdings in Vital Therapies by 51.4% in the third quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock valued at $1,961,000 after purchasing an additional 131,828 shares during the period. Goldman Sachs Group Inc. grew its holdings in Vital Therapies by 261.4% in the second quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after purchasing an additional 168,705 shares during the period. LMR Partners LLP purchased a new stake in Vital Therapies in the second quarter valued at approximately $396,000. Finally, Blair William & Co. IL lifted its position in Vital Therapies by 67.2% during the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after buying an additional 40,000 shares in the last quarter. Hedge funds and other institutional investors own 24.35% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Vital Therapies’ (NASDAQ:VTL) “Buy” Rating Reaffirmed at Raymond James Financial” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/12/16/vital-therapies-vtl-rating-reiterated-by-raymond-james-financial.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply